Crescent Biopharma, Inc.

Crescent Biopharma, Inc.

CBIO·NASDAQ

$17.95

+5.6%
HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$495.05M
EPS-14.7800
P/E Ratio-1.21
Earnings Date07/30/2026

cbio

Revenue

Last Annual Value

10.84M

3-Year CAGR

425%

5-Year CAGR

1%

10-Year CAGR

-6%

Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Competitors Analysis of Revenue

CBIO · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
10.84M
927.4%56.4%89.1% 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
593.00K
6.7%10.6%4.5%
0.00
N/AN/AN/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
0.00
N/AN/AN/A
0.00
N/AN/AN/A
4.90M
2.7%1.9%34.1%
39.55M
-39.2%-18.6%7.4%
35.95M
20.1%-4.7%N/A
154.90M
6.8%12.4%61.6%
Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Fair Value Envelope

CBIO · NASDAQ

Our analysis suggests that CBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $17.955, this represents a potential HIDDEN relative to our calculated worth for Crescent Biopharma, Inc..

Intrinsic Value
Current Price: $17.955